Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683350 | 0.87 | SLC5A2 (0.49) | SLC5A2SLC5A1SNCAMEN1KMT2A | |
| SCHEMBL14248461 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL3679953 | 0.83 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL3682044 | 0.81 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL3674512 | 0.81 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL27792574 | 0.79 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL3803080 | 0.78 | LMNA (0.41) | SLC5A2SLC5A1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1539290 | 0.78 | SLC5A2 (0.52) | SLC5A2SLC5A1ALDH1A1 | |
| SCHEMBL3798647 | 0.77 | SLC5A2 (0.37) | SLC5A2SLC5A1LMNAMAPK1NLRP1 | |
| SCHEMBL27792576 | 0.77 | SLC5A2 (0.36) | SLC5A2SLC5A1LMNAMAPK1NLRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064222-B1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2064222-B1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7838498-B2 | Benzylic glycoside derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838498-B2 | Benzylic glycoside derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838498-B2 | Benzylic glycoside derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| CN-101652377-A | Benzylated glycoside derivatives and methods of use thereof | THERACOS INC US | 2010-02-17 | — | — | CN | disclosed |
| EP-2064222-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008122014-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008122014-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885KDM4E 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.